BASS XI Presentations

Session	Speaker	Presentation
M1	Kao-Tai Tsai	Cancer Research: Design, Analyses, and Recent Advances
M-2	D. Das Purkayastha	Topic 1: An Analysis of Expected Survival Differential in a Lung Cancer Trial: An Iterative Procedure with a Censored Regression Model
M-2	D. Das Purkayastha	Topic 2: Determination of the Best Linear Unbiased Estimates (BLUE) of Incomplete Data for the Analysis of Repeated Measurements in Clinical Trials
M-3	Qiming Liao	Endpoints in HIV Clinical Trials
M-4	Qing Liu	Optimizing Late Stage Clinical Development: A Cost-Effective Approach
M-5	V. Devanarayan	Statistical Considerations in Biomarker Method Development & Validation
M-6	Gang Chen, Kevin Liu, and George Chi, Yong-Cheng Wang	Margin, Sample Size and Tests in the Design of Non-inferiority Trials
M-6	Gang Chen, Kevin Liu, and George Chi, Yong-Cheng Wang	Statistical Method for Active Control Non-inferiority Trials with a Time to Event Endpoint
T-1	Michael J. Brown and Robb J. Muirhead	Multiple Primary Endpoints in Clinical Trials
T-2	Keaven Anderson	Comparison of Optimized Group Sequential and Adaptive Designs
T-2	Kevin Liu	Benefit-Risk Evaluation of Multi-stage Adaptive Designs
T-3	Janet Wittes	Methods for Incorporating Flexibility in Trials
T-4	William R. Meyers and William A. Brenneman	Using Robust Parameter Design in Industrial Experiments
W-1	Charles Anello (FDA)	Critical Path in New Drug Development: An Overview
W-1	H.M. James Hung	Emerging Issues and Considerations in Clinical Trial Design Strategy for Drug Development
W-1	Yi Tsong	Emerging issues and considerations in manufacturing quality control of drug products